Antitumor activity of fenretinide encapsulated in novel based PLA microspheres

Stefano Focaroli, Viviana Salvatore, Silvia Bolzani, Pietro Gobbi, Alessandra Ruggeri & Isabella Orienti
Several studies reported fenretinide (4-HPR) can be used as antitumoral drug in many types of cancer cell lines such as neuroblastoma, mammary carcinoma and melanoma. In vitro 4-HPR inhibits growth of neuroblastoma in a dose dependent manner with an high antitumor activity at 5–10 μM (Ponzoni et al., 1995).The main disadvantage of 4HPR in clinical application is its lipophilic behavior which hinders the possibility to maintain therapeutic concentration for long period of time. To bypass...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.